Shanghai Shyndec Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of June 2025: 8.99%

Shanghai Shyndec Pharmaceutical Co Ltd (600420) has an Asset Resilience Ratio of 8.99% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥1.77 Billion
≈ $258.60 Million USD Cash + Short-term Investments

Total Assets

CN¥19.67 Billion
≈ $2.88 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2004–2024)

This chart shows how Shanghai Shyndec Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check 600420 strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Shyndec Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 600420 market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥1.77 Billion 8.99%
Total Liquid Assets CN¥1.77 Billion 8.99%

Asset Resilience Insights

  • Limited Liquidity: Shanghai Shyndec Pharmaceutical Co Ltd maintains only 8.99% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shanghai Shyndec Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shanghai Shyndec Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
JW Pharmaceutical Corp
KO:001067
Drug Manufacturers - Specialty & Generic 8.17%
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275
Drug Manufacturers - Specialty & Generic 14.80%
Fuan Pharmaceutical Group Co
SHE:300194
Drug Manufacturers - Specialty & Generic 1.34%
DRI Healthcare Trust
TO:DHT-U
Drug Manufacturers - Specialty & Generic 13.91%
Hainan Shuangcheng Pharmaceut
SHE:002693
Drug Manufacturers - Specialty & Generic 1.03%

Annual Asset Resilience Ratio for Shanghai Shyndec Pharmaceutical Co Ltd (2004–2024)

The table below shows the annual Asset Resilience Ratio data for Shanghai Shyndec Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 7.17% CN¥1.43 Billion
≈ $209.41 Million
CN¥19.96 Billion
≈ $2.92 Billion
+6.97pp
2018-12-31 0.20% CN¥33.00 Million
≈ $4.83 Million
CN¥16.46 Billion
≈ $2.41 Billion
+0.07pp
2017-12-31 0.13% CN¥20.00 Million
≈ $2.93 Million
CN¥15.17 Billion
≈ $2.22 Billion
-0.40pp
2016-12-31 0.53% CN¥80.00 Million
≈ $11.71 Million
CN¥15.02 Billion
≈ $2.20 Billion
+0.29pp
2015-12-31 0.24% CN¥10.00 Million
≈ $1.46 Million
CN¥4.14 Billion
≈ $605.43 Million
+0.19pp
2007-12-31 0.05% CN¥371.52K
≈ $54.37K
CN¥713.86 Million
≈ $104.46 Million
-0.04pp
2004-12-31 0.09% CN¥470.44K
≈ $68.84K
CN¥516.19 Million
≈ $75.54 Million
--
pp = percentage points

About Shanghai Shyndec Pharmaceutical Co Ltd

SHG:600420 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.68 Billion
CN¥11.51 Billion CNY
Market Cap Rank
#6751 Global
#1394 in China
Share Price
CN¥8.58
Change (1 day)
-1.27%
52-Week Range
CN¥7.78 - CN¥11.59
All Time High
CN¥17.27
About

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company provides nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and… Read more